Ke Si
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- Extracellular vesicles in disease
- RNA Interference and Gene Delivery
- Circular RNAs in diseases
- Advanced biosensing and bioanalysis techniques
Papers in
-
- Extracellular vesicles in disease 3
- RNA Research and Splicing 1
- RNA Interference and Gene Delivery 1
- CRISPR and Genetic Engineering 1
- Oncology 2
- Cancer Immunotherapy and Biomarkers 1
- Co-authors
- Zhongdang Xiao (4 shared papers)Doulathunnisa Jaffar Ali (3 shared papers)Bo Sun (2 shared papers)Gaofeng Liang (1 shared paper)Baoan Chen (1 shared paper)Yanliang Zhu (1 shared paper)Tian Tian (1 shared paper)Zheng Ye (2 shared papers)
- Journals
- Journal of Experimental & Clinical Cancer Research (2 papers)Experimental Cell Research (1 paper)Journal of Nanobiotechnology (1 paper)Evidence-based Complementary and Alternative Medicine (1 paper)Journal of Drug Delivery Science and Technology (1 paper)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Ke Si
7 papers receiving 656 citations
Ke Si's Hit Papers
Peers
Comparison fields: 5 of 70
- Cancer Research 355
- Molecular Biology 549
- Biomaterials 43
- Biomedical Engineering 103
- Immunology 41
Countries citing papers authored by Ke Si
This map shows the geographic impact of Ke Si's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Si with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Si more than expected).
Fields of papers citing papers by Ke Si
This network shows the impact of papers produced by Ke Si. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Si. The network helps show where Ke Si may publish in the future.
Co-authors
The 25 scholars most cited alongside Ke Si, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer Hit paper breakdown → | 2020 | 561 |
| 2 | 2020 | 38 | |
| 3 | 2023 | 37 | |
| 4 | 2018 | 12 | |
| 5 | 2023 | 10 | |
| 6 | 2025 | 3 | |
| 7 | 2025 | 1 |
About Ke Si
Ke Si is a scholar working on Molecular Biology, Oncology, Small Animals, Pharmacology and Pulmonary and Respiratory Medicine, having authored 7 papers that have together received 662 indexed citations. Recurring topics across this work include Extracellular vesicles in disease (3 papers), RNA Research and Splicing (1 paper), RNA Interference and Gene Delivery (1 paper), Infectious Diseases and Mycology (1 paper), Cancer Immunotherapy and Biomarkers (1 paper), Immunotherapy and Immune Responses (1 paper), Fungal Biology and Applications (1 paper) and CRISPR and Genetic Engineering (1 paper). The work is most often cited by research in Cancer Research (355 citations), Molecular Biology (549 citations), Biomaterials (43 citations), Biomedical Engineering (103 citations) and Immunology (41 citations). Ke Si has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Zhongdang Xiao, Doulathunnisa Jaffar Ali, Bo Sun, Gaofeng Liang, Baoan Chen, Yanliang Zhu, Tian Tian, Zheng Ye, Cong He and Zhanping Li. Their work appears in journals such as Journal of Experimental & Clinical Cancer Research, Experimental Cell Research, Journal of Nanobiotechnology, Evidence-based Complementary and Alternative Medicine and Journal of Drug Delivery Science and Technology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.